for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Enzo Biochem, Inc.

ENZ.N

Latest Trade

3.66USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.33

 - 

4.46

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Harbert Discovery Fund Nominates Two Independent Candidates To Enzo Biochem Board

Sept 17 (Reuters) - Enzo Biochem Inc <ENZ.N>::HARBERT DISCOVERY FUND NOMINATES TWO INDEPENDENT CANDIDATES TO ENZO BIOCHEM BOARD.HARBERT DISCOVERY FUND SAYS SENDS LETTER TO ENZO BIOCHEM SHAREHOLDERS.HARBERT DISCOVERY FUND SAYS BELIEVE ENZO IS DEEPLY UNDERVALUED..HARBERT - CURRENTLY OWNS ABOUT 11.8% OF OUTSTANDING SHARES OF ENZO BIOCHEM.HARBERT DISCOVERY FUND SAYS ATTEMPTED TO ENGAGE IN SUBSTANTIVE, PRIVATE DISCUSSIONS WITH ENZO OVER LAST SEVERAL MONTHS.HARBERT DISCOVERY FUND SAYS HDF'S DIRECTOR CANDIDATES FOR ENZO BIOCHEM ARE FABIAN BLANK AND PETER CLEMENS.HARBERT DISCOVERY FUND - ENZO NOMINEES ARE "WELL-POSITIONED TO CREATE NEAR-TERM VALUE THROUGH A FULL EXPLORATION OF STRATEGIC ALTERNATIVES".HARBERT DISCOVERY FUND SAYS INSTEAD OF CONTINUING TO LITIGATE, ENZO SHOULD LOOK TO MONETIZE NON-CORE PATENTS.HARBERT DISCOVERY FUND - "BULK OF VALUE" AT ENZO COULD BE "UNLOCKED" THROUGH A SALE OF NON-CORE ASSETS.

James Roumell Dissolves Share Stake In Enzo Biochem Inc

July 25 (Reuters) - Enzo Biochem Inc <ENZ.N>::JAMES ROUMELL DISSOLVES SHARE STAKE IN ENZO BIOCHEM INC AS OF JULY 22 - SEC FILING.JAMES ROUMELL SAYS IT HAD REPORTED 4.1 PERCENT STAKE IN ENZO BIOCHEM INC AS OF MARCH 22.JAMES ROUMELL SAYS SOLD ENZO BIOCHEM SHARES OF COMMON STOCK BASED ON BELIEF THAT CO’S STOCK IS "NO LONGER UNDERVALUED".

Enzo Biochem Reports Fiscal Third Quarter And Nine Months Operating Results

June 10 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM REPORTS FISCAL THIRD QUARTER AND NINE MONTHS OPERATING RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.14.Q3 GAAP EARNINGS PER SHARE $0.47.Q3 REVENUE $19.7 MILLION VERSUS $25.2 MILLION.INTELLECTUAL PROPERTY SETTLEMENTS GENERATE APPROXIMATELY $30 MILLION IN CASH IN Q3.EXPECT TO SEE MEANINGFUL SEQUENTIAL QUARTERLY COST REDUCTION IMPROVEMENT THROUGHOUT FISCAL 2020.ASSUMING NO FURTHER CHANGES IN REIMBURSEMENT PROGRAMS, RETURN TO OPERATING PROFITABILITY AT LABS IN EARLY CALENDAR 2020..ENZO BIOCHEM - IN ACTIVE DISCUSSIONS WITH SEVERAL LIFE SCIENCES & MEDICAL DEVICE COS, MANUFACTURERS OF AUTOMATED SYSTEMS FOR STRATEGIC RELATIONSHIPS.ENZO BIOCHEM - DISCUSSIONS INVOLVE DEVELOPING LONG-TERM RELATIONSHIPS IN AUTOMATION & MANUFACTURING, DISTRIBUTION, MARKETING & PRODUCT SALES.

Enzo Biochem Says Co's Unit Enters Into Settlement, License Agreement With Hologic, Grifols S.A

April 22 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM - UNIT ENTERED INTO SETTLEMENT, LICENSE AGREEMENT WITH HOLOGIC, GRIFOLS S.A TO SETTLE ALL OUTSTANDING PATENT DISPUTES AMONG THE PARTIES.ENZO BIOCHEM - TERMS OF AGREEMENT INCLUDE ONE-TIME PAYMENTS OF $14 MILLION TO CO IN EXCHANGE FOR FULLY PAID-UP, WORLDWIDE LICENSES TO HOLOGIC & GRIFOLS.

Harbert Fund Advisors Inc Reports 6.92 Pct Share Stake In Enzo Biochem Inc As Of March 29

April 8 (Reuters) - Enzo Biochem Inc <ENZ.N>::HARBERT FUND ADVISORS INC REPORTS 6.92 PERCENT SHARE STAKE IN ENZO BIOCHEM INC AS OF MARCH 29 - SEC FILING.HARBERT FUND ADVISORS INC SAYS PURCHASED SECURITIES OF ENZO BIOCHEM INC BASED ON BELIEF THAT SECURITIES WERE "UNDERVALUED".

James Roumell Reports 4.1 Pct Stake In Enzo Biochem

March 26 (Reuters) - Enzo Biochem Inc <ENZ.N>::JAMES ROUMELL REPORTS 4.1 PERCENT SHARE STAKE IN ENZO BIOCHEM INC AS OF MARCH 22 - SEC FILING.JAMES C. ROUMELL - AS OF MARCH 22, DECIDED TO SEND LETTER TO ENZO BIOCHEM BOARD TO ASK IT REVIEW STRATEGIC OPTIONS.JAMES C. ROUMELL - SENT A LETTER, DATED MARCH 26, 2019, TO ENZO BOARD OF DIRECTORS.JAMES ROUMELL SAYS ACQUIRED ENZO BIOCHEM SHARES FOR INVESTMENT PURPOSES, BASED ON BELIEF THAT CO'S STOCK IS UNDERVALUED.JAMES ROUMELL SAYS MAY ALSO ENTER INTO DISCUSSIONS WITH THIRD PARTIES AND OTHER STOCKHOLDERS OF ENZO BIOCHEM INC.

Enzo Biochem Reports Q2 Non-GAAP Loss Per Share of $0.18

March 11 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM REPORTS SECOND FISCAL QUARTER AND FIRST HALF 2019 RESULTS AND REPORTS PROGRESS ON ITS INVESTMENTS AND STRATEGIC GOALS.Q2 REVENUE $19.3 MILLION VERSUS $26.1 MILLION.Q2 NON-GAAP LOSS PER SHARE $0.18.

Enzo Biochem Enters Settlement Agreement With Roche

Feb 11 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM INC - CO ALONG WITH ITS UNIT ENTERED INTO A SETTLEMENT AGREEMENT AS OF FEBRUARY 5, 2019 WITH ROCHE - SEC FILING.ENZO BIOCHEM INC - ROCHE HAS AGREED TO PAY $21 MILLION IN SETTLEMENT PURSUANT TO AGREEMENT.

Enzo Biochem Q1 Loss Per Share $0.13

Dec 10 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM REPORTS FISCAL 2019 FIRST QUARTER RESULTS.Q1 REVENUE $21.3 MILLION VERSUS $26.9 MILLION.Q1 NON-GAAP LOSS PER SHARE $0.13.TOTAL CASH AND CASH EQUIVALENTS AT OCTOBER 31, 2018 WERE $52.8 MILLION COMPARED TO $60.0 MILLION AT JULY 31, 2018.

Enzo Biochem Reports Fourth Quarter And Fiscal 2018 Results

Oct 15 (Reuters) - Enzo Biochem Inc <ENZ.N>::ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL 2018 RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.12.QTRLY GAAP AND NON-GAAP NET LOSS PER SHARE $0.12.QTRLY TOTAL REVENUES WERE $24.5 MILLION VERSUS $28.2 MILLION.TOTAL CASH AND CASH EQUIVALENTS AT JULY 31, 2018 WERE $60.0 MILLION COMPARED TO $64.2 MILLION AT JULY 31, 2017.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up